Figure S3. Goodness-of-fit plots for landmark exposure-response models of ACR20, ACR50, and ACR70 responses at Week 24 using Cave,ss (a) as an exposure metric and at Week 20 using Ctrough,wk20 as an exposure metric (b) and of IGA0/1 and IGA0 at Week 24 using Cave,ss (c) as an exposure metric.

The observed response rates (squares) and corresponding 90% confidence intervals were determined according to the bins for the model-predicted guselkumab exposure metrics and were plotted as the median exposure for each bin. The solid lines are the simulated median responses. The dotted lines and shaded areas both represent the simulated 90% prediction intervals from 1000 simulations incorporating model parameter uncertainties. The solid lines at the bottom of the chart show the 5th to the 95th percentile for the exposure metrics, and the circles are plotted at the median values for the 100 mg q8w and 100 mg q4w treatment groups, respectively.

ACR, American College of Rheumatology; ACR20/ACR50/ACR70, 20%, 50%, or 70% improvement in arthritis activity relative to baseline; Cave,ss, average concentration at steady state; Ctrough,wk20, trough serum concentration at Week 20; GUS, guselkumab; IGA, Investigator’s Global Assessment; IGA0, IGA score of cleared (0); IGA0/1, IGA score of cleared (0) or minimal (1); Q4W, every 4 weeks; Q8W, every 8 weeks.